<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Lee TW</submitter><funding>Gyeongsang National University Changwon Hospital</funding><pagination>8353</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12428576</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>26(17)</volume><pubmed_abstract>Rhabdomyolysis is characterized by the breakdown of skeletal muscle tissue, frequently leading to acute kidney injury (AKI). Traditional conservative treatments have shown limited effectiveness in modifying the disease course, thereby necessitating targeted pharmacological approaches. Zileuton (Z), a selective inhibitor of 5-lipoxygenase (5-LOX), has demonstrated efficacy in enhancing renal function recovery in animal models of AKI induced by agents such as cisplatin, aminoglycosides, and polymyxins. The present study aimed to evaluate the therapeutic potential of a single dose of Z in mitigating rhabdomyolysis-induced AKI (RI-AKI) via modulation of myeloid-derived suppressor cells (MDSCs). Male C57BL/6 mice were assigned to four experimental groups: Sham (intraperitoneal administration of</pubmed_abstract><journal>International journal of molecular sciences</journal><pubmed_title>Zileuton Attenuates Acute Kidney Injury in Glycerol-Induced Rhabdomyolysis by Regulating Myeloid-Derived Suppressor Cells in Mice.</pubmed_title><pmcid>PMC12428576</pmcid><funding_grant_id>GNUCHBRIF-2024-01</funding_grant_id><pubmed_authors>Bae E</pubmed_authors><pubmed_authors>Jung MH</pubmed_authors><pubmed_authors>Lee TW</pubmed_authors><pubmed_authors>Kim JH</pubmed_authors><pubmed_authors>Park DJ</pubmed_authors></additional><is_claimable>false</is_claimable><name>Zileuton Attenuates Acute Kidney Injury in Glycerol-Induced Rhabdomyolysis by Regulating Myeloid-Derived Suppressor Cells in Mice.</name><description>Rhabdomyolysis is characterized by the breakdown of skeletal muscle tissue, frequently leading to acute kidney injury (AKI). Traditional conservative treatments have shown limited effectiveness in modifying the disease course, thereby necessitating targeted pharmacological approaches. Zileuton (Z), a selective inhibitor of 5-lipoxygenase (5-LOX), has demonstrated efficacy in enhancing renal function recovery in animal models of AKI induced by agents such as cisplatin, aminoglycosides, and polymyxins. The present study aimed to evaluate the therapeutic potential of a single dose of Z in mitigating rhabdomyolysis-induced AKI (RI-AKI) via modulation of myeloid-derived suppressor cells (MDSCs). Male C57BL/6 mice were assigned to four experimental groups: Sham (intraperitoneal administration of</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Aug</publication><modification>2026-05-26T20:04:33.652Z</modification><creation>2026-05-26T03:06:37.636Z</creation></dates><accession>S-EPMC12428576</accession><cross_references><pubmed>40943295</pubmed><doi>10.3390/ijms26178353</doi></cross_references></HashMap>